Search research articles
Contact Us
Filters
Showing results (61-70 of 118) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2023
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Jennifer J Gao, Christy L Osgood, Zhou Feng, et al.
JNCI Cancer Spectrum
|
July 16, 2025
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials
Elaine Chang, Haley Gittleman, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2010
Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary
Shakun M Malik, Ke Liu, Xu Qiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2013
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary
Paul G Kluetz, William Pierce, V Ellen Maher, et al.
JAMA Oncology
|
December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung Cancer
Yufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2015
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer
Sean Khozin, Gideon M Blumenthal, Lijun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Mirat Shah, Ting-Yu Chen, Gwynn Ison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2019
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
Lynn J Howie, Harpreet Singh, Erik Bloomquist, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 118) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2019
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
V Ellen Maher, Laura L Fernandes, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 18, 2023
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Jennifer J Gao, Christy L Osgood, Zhou Feng, et al.
JNCI Cancer Spectrum
|
July 16, 2025
The Food and Drug Administration pooled analysis of overall survival according to depth of response in frontline advanced immune-oncology renal cell carcinoma trials
Elaine Chang, Haley Gittleman, Chi Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2010
Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary
Shakun M Malik, Ke Liu, Xu Qiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2013
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary
Paul G Kluetz, William Pierce, V Ellen Maher, et al.
JAMA Oncology
|
December 29, 2022
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
Sundeep Agrawal, Shaily Arora, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung Cancer
Yufan Liu, Jeannette Nashed, Amy K Barone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2015
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer
Sean Khozin, Gideon M Blumenthal, Lijun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Mirat Shah, Ting-Yu Chen, Gwynn Ison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2019
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
Lynn J Howie, Harpreet Singh, Erik Bloomquist, et al.
Page
of 12